

Package leaflet: Information for the patient

Dolutegravir, lamivudine and tenofovir disoproxil fumarate tablets 50 / 300 / 300 mg

Dolutegravir, lamivudine and tenofovir disoproxil fumarate

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

- Keep this leaflet, you may need to read it again.
- If you have further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet:

1. What Dolutegravir, lamivudine and tenofovir disoproxil fumarate tablets is and what it is used for
2. What you need to know before you take Dolutegravir, lamivudine and tenofovir disoproxil fumarate tablets
3. How to take Dolutegravir, lamivudine and tenofovir disoproxil fumarate tablets
4. Possible side effects
5. How to store dolutegravir, lamivudine and tenofovir disoproxil fumarate tablets
6. Contents of the pack and other information

1. What Dolutegravir, lamivudine and tenofovir disoproxil fumarate tablets is and what it is used for

Dolutegravir, lamivudine and tenofovir disoproxil fumarate tablets is a medicine that contains three active ingredients : Dolutegravir, lamivudine and tenofovir disoproxil fumarate. Dolutegravir belongs to a group of anti-retroviral medicines called integrase inhibitors. Tenofovir is a nucleotide reverse transcriptase inhibitor, while lamivudine belongs to the group of the nucleoside analogue reverse transcriptase inhibitors.

- Dolutegravir, lamivudine and tenofovir disoproxil fumarate tablets is used to treat Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and children who weigh at least 88 pounds (40 kg).
- HIV-1 is the virus that causes Acquired Immune Deficiency Syndrome (AIDS).

2. What you need to know before you take Dolutegravir, lamivudine and tenofovir disoproxil fumarate tablets

Do not take Dolutegravir, lamivudine and tenofovir disoproxil fumarate tablets

- if you are allergic to dolutegravir, lamivudine and tenofovir disoproxil fumarate or any of the other ingredients of this medicine.

Warnings and precautions

Liver disease

Worsening of liver disease that has caused death has happened in people infected with both HIV-1 and hepatitis C virus who were taking antiretroviral medicines for HIV-1 and were also being treated for hepatitis C with interferon alfa with or without ribavirin. If you are taking dolutegravir,

lamivudine and tenofovir disoproxil fumarate tablets and interferon with or without ribavirin, tell your healthcare provider if you have any new symptoms.

Risk of inflammation of the pancreas

Children may be at risk for developing pancreatitis during treatment with dolutegravir, lamivudine and tenofovir disoproxil fumarate tablets if they:

- have taken nucleoside analogue medicines in the past
- have a history of pancreatitis
- have other risk factors for pancreatitis

Call your healthcare provider right away if your child develops signs and symptoms of pancreatitis including severe upper stomach-area pain, with or without nausea and vomiting. Your healthcare provider may tell you to stop giving dolutegravir, lamivudine and tenofovir disoproxil fumarate tablets to your child if their symptoms and blood test results show that your child may have pancreatitis.

Kidney diseases

Your healthcare provider may do blood and urine tests to check your kidneys before and during treatment with dolutegravir, lamivudine and tenofovir disoproxil fumarate tablets. Tell your healthcare provider if you get signs and symptoms of kidney problems, including bone pain that does not go away or worsening bone pain, pain in your arms, hands, legs, or feet, broken (fractured) bones, muscle pain or weakness.

Bone problems

Bone problems can happen in some people who take dolutegravir, lamivudine and tenofovir disoproxil fumarate tablets. Bone problems include bone pain, softening or thinning (which may lead to fractures). Your healthcare provider may need to do additional tests to check your bones. Tell your healthcare provider if you have any bone pain, pain in your hands or feet, or muscle pain or weakness during treatment with dolutegravir, lamivudine and tenofovir disoproxil fumarate tablets.

Immune reconstitution syndrome

Changes in your immune system can happen when you start taking HIV-1 medicines. Your immune system may get stronger and begin to fight infections that have been hidden in your body for a long time. Tell your healthcare provider right away if you start having new symptoms after you start taking dolutegravir, lamivudine and tenofovir disoproxil fumarate tablets.

Lactic acidosis

Lactic acidosis is a serious medical emergency that can lead to death. Tell your healthcare provider right away if you get any of the following symptoms that could be signs of lactic acidosis:

- feel very weak or tired
- unusual (not normal) muscle pain
- trouble breathing
- stomach pain with nausea and vomiting
- feel cold, especially in your arms and legs
- feel dizzy or light-headed
- have a fast or irregular heartbeat

Children and adolescents

Dolutegravir, lamivudine and tenofovir disoproxil fumarate is suitable only for children and young people who weigh at least 40 kg.

Other medicines and Dolutegravir, lamivudine and tenofovir disoproxil fumarate tablets

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

You must not take dolutegravir, lamivudine and tenofovir disoproxil fumarate with dofetilide, which is used to treat heart conditions.

Tell your health care provider if you are taking any of the following:

- metformin, to treat diabetes
- antacids, to treat indigestion and heartburn. Do not take an antacid during the 6 hours before you take dolutegravir, lamivudine and tenofovir disoproxil fumarate tablet, or for at least 2 hours after you take it
- calcium supplements, iron supplements and multivitamins. Do not take a calcium supplement, iron supplement or multivitamin during the 6 hours before you take dolutegravir, lamivudine and tenofovir disoproxil fumarate, or for at least 2 hours after you take it
- etravirine, efavirenz, fosamprenavir/ritonavir, nevirapine or tipranavir/ritonavir, to treat HIV infection
- phenytoin and phenobarbital, to treat epilepsy
- oxcarbazepine and carbamazepine, to treat epilepsy or bipolar disorder
- St John's wort (*Hypericum perforatum*), a herbal remedy used for treating depression
- other medicines containing tenofovir disoproxil, emtricitabine, lamivudine or zalcitabine to treat HIV infection

It is very important to tell your health care provider if you are taking other medicines that may damage your kidneys. These include:

- aminoglycosides (for bacterial infection)
- ganciclovir, or cidofovir (for viral infection)
- adefovir dipivoxil (for hepatitis B virus infection)
- tacrolimus (for suppression of the immune system)
- non-steroidal anti-inflammatory drugs (NSAIDs, to relieve bone or muscle pains).

Other medicines containing didanosine (for HIV infection)

Taking dolutegravir, lamivudine and tenofovir disoproxil fumarate with medicines that contain didanosine can increase the amount of didanosine in your blood. Rarely, inflammation of the pancreas and lactic acidosis (excess lactic acid in the blood), sometimes causing death, has been reported when medicines containing tenofovir disoproxil and didanosine were taken together. Combining tenofovir disoproxil with didanosine can also reduce the effects of antiretroviral therapy. Your health care provider will carefully consider whether to treat you with a combination of tenofovir disoproxil and didanosine.

If you are taking another antiviral medicine called a protease inhibitor to treat HIV, your healthcare provider may order blood tests to closely monitor your kidney function.

It is also important to tell your health care provider if you are taking ledipasvir/sofosbuvir, sofosbuvir/velpatasvir or sofosbuvir/velpatasvir/ voxilaprevir to treat hepatitis C infection.

Pregnancy and breast-feeding

- If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

- If you are pregnant or plan to become pregnant. One of the medicines in dolutegravir, lamivudine and tenofovir disoproxil fumarate tablets called dolutegravir may harm your unborn baby.
- You should not take dolutegravir, lamivudine and tenofovir disoproxil fumarate tablets at the time of becoming pregnant or during the first 12 weeks of pregnancy. Your healthcare provider may change your medicine during this time in your pregnancy.
- If you can become pregnant, your healthcare provider will perform a pregnancy test before you start treatment with dolutegravir, lamivudine and tenofovir disoproxil fumarate tablets.
- If you can become pregnant, you should consistently use effective birth control (contraception) during treatment with dolutegravir, lamivudine and tenofovir disoproxil fumarate tablets.
- Tell your healthcare provider right away if you are planning to become pregnant, you become pregnant, or think you may be pregnant during treatment with dolutegravir, lamivudine and tenofovir disoproxil fumarate tablets.
- If you are breastfeeding or plan to breastfeed. Do not breastfeed if you take dolutegravir, lamivudine and tenofovir disoproxil fumarate tablets.
- You should not breastfeed if you have HIV-1 because of the risk of passing HIV-1 to your baby. Talk with your healthcare provider about the best way to feed your baby.

Driving and using machines

Dolutegravir, lamivudine and tenofovir disoproxil fumarate tablets has no or negligible influence on the ability to drive and use machines.

Dolutegravir, lamivudine and tenofovir disoproxil fumarate tablet contains Sodium

This medicinal product also contains less than 23 mg sodium per dosage unit, that is to say essentially 'sodium-free'.

3. How to take Dolutegravir, lamivudine and tenofovir disoproxil fumarate tablet

Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.

- For adults and children weighing at least 40 kg (88 lbs), the usual dose of dolutegravir, lamivudine and tenofovir disoproxil fumarate tablets is one tablet each day. An extra dose of dolutegravir only may be necessary for certain populations. Your healthcare provider will inform you if you need to take the extra dolutegravir dose.
- Take dolutegravir, lamivudine and tenofovir disoproxil fumarate tablets at the same time every day.
- Take dolutegravir, lamivudine and tenofovir disoproxil fumarate each day with or without food.
- If you take antacids, laxatives, or other medicines that contain aluminum, magnesium, or buffered medicines, dolutegravir, lamivudine and tenofovir disoproxil fumarate tablets should be taken at least 2 hours before or 6 hours after you take these medicines.
- If you need to take iron or calcium supplements by mouth during treatment with dolutegravir, lamivudine and tenofovir disoproxil fumarate tablets:
 - If you take dolutegravir, lamivudine and tenofovir disoproxil fumarate tablets with food, you may take these supplements at the same time that you take dolutegravir, lamivudine and tenofovir disoproxil fumarate tablets.
 - If you do not take dolutegravir, lamivudine and tenofovir disoproxil fumarate tablets with food, take dolutegravir, lamivudine and tenofovir disoproxil fumarate tablets at least 2 hours before or 6 hours after you take these supplements.

Children and adolescents

The dose of dolutegravir, lamivudine and tenofovir disoproxil fumarate in children and adolescents weighing at least 40 kg is one tablet once a day.

If you take more dolutegravir, lamivudine and tenofovir disoproxil fumarate tablet than you should

- If you take too many dolutegravir, lamivudine and tenofovir disoproxil fumarate tablets, go to the nearest hospital emergency room right away.

If you forget to take dolutegravir, lamivudine and tenofovir disoproxil fumarate tablet

- Do not miss a dose of dolutegravir, lamivudine and tenofovir disoproxil fumarate tablets. If you miss a dose of dolutegravir, lamivudine and tenofovir disoproxil fumarate tablets, take them as soon as you remember. If it is almost time for your next dose of dolutegravir, lamivudine and tenofovir disoproxil fumarate tablets, do not take the missed dose. Take the next dose of dolutegravir, lamivudine and tenofovir disoproxil fumarate tablets at your regular time.
- Do not take a double dose of dolutegravir, lamivudine and tenofovir disoproxil fumarate tablet to make up for a forgotten dose.

If you stop taking dolutegravir, lamivudine and tenofovir disoproxil fumarate tablet

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Allergic reactions

Call your healthcare provider right away if you develop a rash with dolutegravir, lamivudine and tenofovir disoproxil fumarate tablets. Stop taking dolutegravir, lamivudine and tenofovir disoproxil fumarate tablets and get medical help right away if you:

develop a rash with any of the following signs or symptoms:

- Fever,
- generally ill feeling,
- tiredness,
- muscle or joint aches,
- blisters or sores in mouth,
- blisters or peeling of the skin,
- redness or swelling of the eyes,
- swelling of the mouth, face, lips, or tongue,
- problems breathing.

Very common side effects (may affect more than 1 in 10 people)

- headache diarrhoea,
- feeling sick (nausea),
- difficulty in sleeping (insomnia).

Common side effects (may affect up to 1 in 10 people)

- rash, itching (pruritus),
- being sick (vomiting),
- abdominal (belly) pain and discomfort, wind (flatulence),
- insomnia, abnormal dreams, depression,
- dizziness, tiredness

Uncommon side effects (may affect up to 1 in 100 people)

- allergic reaction,
- pain in the tummy (abdomen) caused by inflammation of the pancreas,
- yellow skin or eyes, itching, or pain in the abdomen (tummy) caused by inflammation of the liver joint and muscle pain,
- bone pain and bone fracture which may be caused by kidney damage (see Warnings and precautions). suicidal thoughts and behaviours (particularly in patients who have had depression or mental health problems before)

Rare side effects (may affect up to 1 in 1000 people)

- lactic acidosis (excess of lactic acid in the blood),
- inflammation of the kidney, passing a lot of urine and feeling thirsty
- changes to your urine and back pain caused by kidney problems, including kidney failure

Very rare side effects (may affect up to 1 in 10000 people)

- a failure of the bone marrow to produce new red blood cells (pure red cell aplasia).

Not known side effects

- appearance of symptoms of infection as part of the 'immune reactivation syndrome.

Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via local reporting system. By reporting side effects, you can help provide more information on the safety of this medicine.

5. How to store dolutegravir, lamivudine and tenofovir disoproxil fumarate

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date, which is stated on the bottle pack after 'EXP'. The expiry date refers to the last day of that month.

Store below 30°C (86°F)

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.

6. Contents of the pack and other information

What dolutegravir, lamivudine and tenofovir disoproxil fumarate tablet contains

- The active substances are dolutegravir, lamivudine and tenofovir disoproxil fumarate tablets 50/ 300/ 300 mg
- The other ingredients are:
 - Tablet core
Mannitol, Microcrystalline Cellulose, Sodium Starch Glycolate, Povidone, Purified Water, Croscarmellose Sodium, Magnesium Stearate
 - Film-coating
Polyvinyl Alcohol, Triacetin, Talc, Sodium Lauryl Sulfate, Titanium dioxide, FD&C Blue No.2 Al. Lake, FD&C Blue No.1 Al. Lake, Purified water

What dolutegravir, lamivudine and tenofovir disoproxil fumarate looks like and contents of the pack

Film- coated tablet.

Blue coloured, capsule shaped biconvex film coated tablet, debossed with 'C' on one side and plain on other side.

30's container

HDPE bottle of 30 tablets with desiccant, induction seal, and non-child resistant closure carton containing 30's container: HDPE bottle of 30 tablets with desiccant, induction seal, and non-child resistant closure

90's container

HDPE bottle of 90 tablets with desiccant, induction seal, and non-child resistant closure 90's container: HDPE bottle of 90 tablets with desiccant, induction seal, and non-child resistant closure

180's container

HDPE bottle of 90 tablets with desiccant, induction seal, and non-child resistant closure 180's container: HDPE bottle of 180 tablets with desiccant, induction seal, and non-child resistant closure

Marketing Authorisation Holder and manufacturer

Cipla Ltd., India

This leaflet was last revised in {MM/YYYY}

[Item to be completed at the time of approval]